Beijing Hotgen Biotech Co Ltd (688068) — Cash Flow-to-Debt Ratio
Beijing Hotgen Biotech Co Ltd (688068) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥3.05 Million could theoretically repay 0% of its total liabilities (CN¥278.25 Million) in one year. See Beijing Hotgen Biotech Co Ltd (688068) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing Hotgen Biotech Co Ltd Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Beijing Hotgen Biotech Co Ltd across 9 annual periods. Also explore Beijing Hotgen Biotech Co Ltd (688068) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Beijing Hotgen Biotech Co Ltd (2016–2024)
Year-by-year debt coverage analysis for Beijing Hotgen Biotech Co Ltd. For market capitalisation and broader financial context, see Beijing Hotgen Biotech Co Ltd (688068) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | CN¥-37.16 Million | CN¥251.77 Million | ▼ -17.8% |
| 2023 | -0.13x | CN¥-25.39 Million | CN¥202.56 Million | ▼ -107.0% |
| 2022 | 1.79x | CN¥978.75 Million | CN¥545.59 Million | ▼ -47.7% |
| 2021 | 3.43x | CN¥2.64 Billion | CN¥771.01 Million | ▲ +224.4% |
| 2020 | 1.06x | CN¥164.62 Million | CN¥155.72 Million | ▲ +316.8% |
| 2019 | 0.25x | CN¥19.37 Million | CN¥76.37 Million | ▼ -73.9% |
| 2018 | 0.97x | CN¥55.04 Million | CN¥56.68 Million | ▲ +18.5% |
| 2017 | 0.82x | CN¥22.95 Million | CN¥28.00 Million | ▼ -47.6% |
| 2016 | 1.56x | CN¥45.54 Million | CN¥29.14 Million | — |